{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Miller VM"],"funding":["National Center for Research Resources","Mayo Foundation for Medical Education and Research","NCATS NIH HHS","NIA NIH HHS","NCRR NIH HHS","NHLBI NIH HHS","Aurora Foundation","NINDS NIH HHS","National Institutes of Health","Veterans Health Administration"],"pagination":["139-145"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8108428"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(2)"],"pubmed_abstract":["The Kronos Early Estrogen Prevention Study (KEEPS) was a randomized, double-blind, placebo-controlled trial designed to determine the effects of hormone treatments (menopausal hormone treatments [MHTs]) on the progression of carotid intima-medial thickness (CIMT) in recently menopausal women. Participants less than 3 years from menopause and without a history of overt cardiovascular disease (CVD), defined as no clinical CVD events and coronary artery calcium < 50 Agatston units, received either oral conjugated equine estrogens (0.45 mg/day) or transdermal 17β-estradiol (50 µg/day), both with progesterone (200 mg/day for 12 days/month), or placebo pills and patches for 4 years. Although MHT did not decrease the age-related increase in CIMT, KEEPS provided other important insights about MHT effects. Both MHTs versus placebo reduced the severity of menopausal symptoms and maintained bone density, but differed in efficacy regarding mood/anxiety, sleep, sexual function, and deposition of β-amyloid in the brain. Additionally, genetic variants in enzymes for metabolism and uptake of estrogen affected the efficacy of MHT for some aspects of symptom relief. KEEPS provides important information for use of MHT in clinical practice, including type, dose, and mode of delivery of MHT recently after menopause, and how genetic variants in hormone metabolism may affect MHT efficacy on specific outcomes."],"journal":["Climacteric : the journal of the International Menopause Society"],"pubmed_title":["Lessons from KEEPS: the Kronos Early Estrogen Prevention Study."],"pmcid":["PMC8108428"],"funding_grant_id":["HL90639, P50 AG44170, RF1 AG057547, R21 NS066147","P50 AG044170","none","UL1 TR001863","Ul1 RR024150, Ul1 RR024139, Ul1 RR02413","RF1 AG057547","R21 NS066147","R01 HL090639","UL1 RR024139","Kronos Longevity Research Center","UL1 RR024131","UL1 RR024150","U54 AG044170"],"pubmed_authors":["Kling JM","Manson JE","Dowling NM","Harman SM","Taylor HS","Brinton EA","Cedars MI","Gleason CE","Miller VM","Naftolin F","Kantarci K"],"additional_accession":[]},"is_claimable":false,"name":"Lessons from KEEPS: the Kronos Early Estrogen Prevention Study.","description":"The Kronos Early Estrogen Prevention Study (KEEPS) was a randomized, double-blind, placebo-controlled trial designed to determine the effects of hormone treatments (menopausal hormone treatments [MHTs]) on the progression of carotid intima-medial thickness (CIMT) in recently menopausal women. Participants less than 3 years from menopause and without a history of overt cardiovascular disease (CVD), defined as no clinical CVD events and coronary artery calcium < 50 Agatston units, received either oral conjugated equine estrogens (0.45 mg/day) or transdermal 17β-estradiol (50 µg/day), both with progesterone (200 mg/day for 12 days/month), or placebo pills and patches for 4 years. Although MHT did not decrease the age-related increase in CIMT, KEEPS provided other important insights about MHT effects. Both MHTs versus placebo reduced the severity of menopausal symptoms and maintained bone density, but differed in efficacy regarding mood/anxiety, sleep, sexual function, and deposition of β-amyloid in the brain. Additionally, genetic variants in enzymes for metabolism and uptake of estrogen affected the efficacy of MHT for some aspects of symptom relief. KEEPS provides important information for use of MHT in clinical practice, including type, dose, and mode of delivery of MHT recently after menopause, and how genetic variants in hormone metabolism may affect MHT efficacy on specific outcomes.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Apr","modification":"2025-04-04T23:01:23.785Z","creation":"2025-02-18T23:32:24.455Z"},"accession":"S-EPMC8108428","cross_references":{"pubmed":["32880220"],"doi":["10.1080/13697137.2020.1804545"]}}